The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004)
To present the results from a randomized, double-blind, phase 1b study assessing the safety, tolerability, and pharmacodynamics of ALKS 2680 in patients with narcolepsy type 1 (NT1).
Authors
- Brendon J. Yee (ORCID: https://orcid.org/0000-0002-2196-8649)
- Daniel J. Smith (ORCID: https://orcid.org/0000-0003-2387-2795)
- Ronald R. Grunstein (ORCID: https://orcid.org/0000-0001-6682-5812)
- Julia L. Chapman (ORCID: https://orcid.org/0000-0001-5512-827X)
- Jandira Ramos
- Bhaskar Rege
- A D’Rozario (ORCID: https://orcid.org/0000-0001-8564-796X)
- Craig Hopkinson
- Sergey Yagoda
Institutions
- Alkermes (Ireland) (IE)
- Woolcock Institute of Medical Research (AU)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210498
- Citations
- 2
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 2.86